Small-Cell Lung Cancer - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 564 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Small-Cell Lung Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Small-Cell Lung Cancer - Pipeline Review, H2 2015', provides an overview of the Small-Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Small-Cell Lung Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Small-Cell Lung Cancer - Overview 12
Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis 13
Small-Cell Lung Cancer - Therapeutics under Development by Companies 14
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 20
Small-Cell Lung Cancer - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Small-Cell Lung Cancer - Products under Development by Companies 25
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 32
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 33
3B Pharmaceuticals GmbH 33
4SC AG 34
A. Menarini Industrie Farmaceutiche Riunite Srl 35
AbbVie Inc. 36
Alchemia Limited 37
Amgen Inc. 38
Andarix Pharmaceuticals, Inc. 39
Aposense Ltd. 40
Array BioPharma Inc. 41
Astellas Pharma Inc. 42
AstraZeneca Plc 43
AVEO Pharmaceuticals, Inc. 44
Bayer AG 45
BIND Therapeutics, Inc. 46
Blend Therapeutics, Inc. 47
Boehringer Ingelheim GmbH 48
Bristol-Myers Squibb Company 49
Cantex Pharmaceuticals, Inc. 50
Celator Pharmaceuticals, Inc. 51
CellAct Pharma GmbH 52
Cellceutix Corporation 53
Cerulean Pharma, Inc. 54
Cornerstone Pharmaceuticals, Inc. 55
Critical Outcome Technologies Inc. 56
CytRx Corporation 57
Double Bond Pharmaceutical International AB 58
Eli Lilly and Company 59
Exelixis, Inc. 60
F. Hoffmann-La Roche Ltd. 61
G1 Therapeutics, Inc. 62
Genzyme Corporation 63
GlaxoSmithKline Plc 64
Hutchison MediPharma Limited 65
Ignyta, Inc. 66
Immunomedics, Inc. 67
Inbiopro Solutions Pvt. Ltd. 68
Johnson & Johnson 69
Karyopharm Therapeutics, Inc. 70
Kolltan Pharmaceuticals, Inc. 71
Kyowa Hakko Kirin Co., Ltd. 72
Lindis Biotech GmbH 73
MabVax Therapeutics Holdings, Inc. 74
MedImmune, LLC 75
MEI Pharma, Inc. 76
Merck & Co., Inc. 77
Mersana Therapeutics, Inc. 78
Millennium Pharmaceuticals, Inc. 79
Mirna Therapeutics, Inc. 80
MolMed S.p.A. 81
Mologen AG 82
NanoSmart Pharmaceuticals, Inc. 83
Nektar Therapeutics 84
Nippon Kayaku Co., Ltd. 85
Novartis AG 86
Omnitura Therapeutics Inc. 87
OncoMed Pharmaceuticals, Inc. 88
Ono Pharmaceutical Co., Ltd. 89
Onxeo SA 90
Onyx Pharmaceuticals, Inc. 91
Oxford BioTherapeutics Ltd 92
Pfizer Inc. 93
Polaris Pharmaceuticals, Inc. 94
Rexahn Pharmaceuticals, Inc. 95
Spectrum Pharmaceuticals, Inc. 96
Sumitomo Dainippon Pharma Co., Ltd. 97
Synta Pharmaceuticals Corp. 98
Tesaro, Inc. 99
Vertex Pharmaceuticals Incorporated 100
Zensun (Shanghai) Sci & Tech Co., Ltd. 101
Small-Cell Lung Cancer - Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Target 104
Assessment by Mechanism of Action 112
Assessment by Route of Administration 118
Assessment by Molecule Type 120
Drug Profiles 122
(irinotecan hydrochloride + cisplatin) - Drug Profile 122
3BP-227 - Drug Profile 123
4SC-202 - Drug Profile 124
ABT-737 - Drug Profile 126
Adva-27a - Drug Profile 128
aldoxorubicin hydrochloride - Drug Profile 130
alisertib - Drug Profile 133
Alocrest - Drug Profile 137
amrubicin hydrochloride - Drug Profile 139
ATT-11T - Drug Profile 141
AV-203 - Drug Profile 142
AZD-2811 - Drug Profile 143
AZD-3965 - Drug Profile 144
BAY-1112054 - Drug Profile 146
belinostat - Drug Profile 147
binimetinib - Drug Profile 150
BIW-8962 - Drug Profile 155
BMS-986012 - Drug Profile 156
BMS-986158 - Drug Profile 157
cabozantinib s-malate - Drug Profile 158
CAP-7.1 - Drug Profile 162
carboplatin - Drug Profile 164
carfilzomib - Drug Profile 165
Cellular Immunotherapy 2 for Oncology - Drug Profile 169
COTI-2 - Drug Profile 170
COTI-219 - Drug Profile 173
COTI-4 - Drug Profile 174
COTI-58 - Drug Profile 175
CPI-613 - Drug Profile 176
CRLX-101 - Drug Profile 179
CX-01 - Drug Profile 182
Cyt-PLAT - Drug Profile 184
DTP-348 - Drug Profile 185
durvalumab + tremelimumab - Drug Profile 187
erismodegib - Drug Profile 189
etirinotecan pegol - Drug Profile 192
etoposide phosphate next generation - Drug Profile 195
G-1T28 - Drug Profile 196
ganetespib - Drug Profile 198
GSK-2879552 - Drug Profile 203
GSK-525762 - Drug Profile 204
HMPL-453 - Drug Profile 205
HuMab-5B1 - Drug Profile 206
IBPM-002BZ - Drug Profile 207
ipilimumab - Drug Profile 208
irinotecan hydrochloride - Drug Profile 213
JNJ-42756493 - Drug Profile 215
KIT-SG3227 - Drug Profile 217
KM-3174 - Drug Profile 219
LY-2510924 - Drug Profile 223
ME-344 - Drug Profile 225
MGN-1703 - Drug Profile 227
MK-2206 + selumetinib sulfate - Drug Profile 231
Monoclonal Antibodies to Inhibit Vasopressin V2 Receptor for Small-Cell Lung Cancer - Drug Profile 233
MRX-34 - Drug Profile 234
MX-225 - Drug Profile 236
NGR-hTNF - Drug Profile 237
nintedanib - Drug Profile 241
niraparib - Drug Profile 246
nivolumab - Drug Profile 248
NK-012 - Drug Profile 256
olaparib - Drug Profile 258
OMN-54 - Drug Profile 262
OSI-930 - Drug Profile 264
OX-004 - Drug Profile 265
pasireotide ER - Drug Profile 266
pegargiminase - Drug Profile 268
pembrolizumab - Drug Profile 272
PEN-221 - Drug Profile 281
PF-4989216 - Drug Profile 282
Recombinant Peptide to Target EGFR for Oncology - Drug Profile 283
RG-6016 - Drug Profile 284
roniciclib - Drug Profile 286
rovalpituzumab tesirine - Drug Profile 288
RRX-001 - Drug Profile 289
RX-3117 - Drug Profile 291
SA-083 - Drug Profile 292
sabarubicin - Drug Profile 293
sacituzumab - Drug Profile 295
SC-002 - Drug Profile 297
selinexor - Drug Profile 298
Small Molecules for Small Cell Lung Cancer - Drug Profile 304
Small Molecules to Inhibit eIF-4A for Oncology - Drug Profile 305
Small Molecules to Inhibit EZH2-EED for Cancer - Drug Profile 306
solitomab - Drug Profile 307
STA-128666 - Drug Profile 308
STA-129183 - Drug Profile 310
Synthetic Peptides for Small Cell Lung Cancer and Breast Cancer - Drug Profile 311
taladegib - Drug Profile 312
tarextumab - Drug Profile 313
TF-2 - Drug Profile 315
topotecan hydrochloride - Drug Profile 317
Tozaride - Drug Profile 318
TRBS-07 - Drug Profile 320
ulocuplumab - Drug Profile 321
Vaccine for Small Cell Lung Cancer - Drug Profile 323
vandetanib - Drug Profile 325
veliparib - Drug Profile 331
vorinostat - Drug Profile 335
VX-970 - Drug Profile 339
X-396 - Drug Profile 340
XMT-1001 - Drug Profile 341
ZS-05 - Drug Profile 343
Small-Cell Lung Cancer - Recent Pipeline Updates 344
Small-Cell Lung Cancer - Dormant Projects 541
Small-Cell Lung Cancer - Discontinued Products 547
Small-Cell Lung Cancer - Product Development Milestones 548
Featured News & Press Releases 548
Appendix 555
Methodology 555
Coverage 555
Secondary Research 555
Primary Research 555
Expert Panel Validation 555
Contact Us 555
Disclaimer 556

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H2 2015 20
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2015 21
Number of Products under Development by Companies, H2 2015 23
Number of Products under Development by Companies, H2 2015 (Contd..1) 24
Number of Products under Development by Companies, H2 2015 (Contd..2) 25
Number of Products under Development by Companies, H2 2015 (Contd..3) 26
Number of Products under Development by Companies, H2 2015 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2015 28
Comparative Analysis by Late Stage Development, H2 2015 29
Comparative Analysis by Clinical Stage Development, H2 2015 30
Comparative Analysis by Early Stage Development, H2 2015 31
Comparative Analysis by Unknown Stage Development, H2 2015 32
Products under Development by Companies, H2 2015 33
Products under Development by Companies, H2 2015 (Contd..1) 34
Products under Development by Companies, H2 2015 (Contd..2) 35
Products under Development by Companies, H2 2015 (Contd..3) 36
Products under Development by Companies, H2 2015 (Contd..4) 37
Products under Development by Companies, H2 2015 (Contd..5) 38
Products under Development by Companies, H2 2015 (Contd..6) 39
Products under Investigation by Universities/Institutes, H2 2015 40
Small-Cell Lung Cancer - Pipeline by 3B Pharmaceuticals GmbH, H2 2015 41
Small-Cell Lung Cancer - Pipeline by 4SC AG, H2 2015 42
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 43
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2015 44
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H2 2015 45
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H2 2015 46
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015 47
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H2 2015 48
Small-Cell Lung Cancer - Pipeline by Array BioPharma Inc., H2 2015 49
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H2 2015 50
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2015 51
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 52
Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2015 53
Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015 54
Small-Cell Lung Cancer - Pipeline by Blend Therapeutics, Inc., H2 2015 55
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 56
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 57
Small-Cell Lung Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015 58
Small-Cell Lung Cancer - Pipeline by Celator Pharmaceuticals, Inc., H2 2015 59
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2015 60
Small-Cell Lung Cancer - Pipeline by Cellceutix Corporation, H2 2015 61
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 62
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 63
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 64
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H2 2015 65
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2015 66
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2015 67
Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H2 2015 68
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 69
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics, Inc., H2 2015 70
Small-Cell Lung Cancer - Pipeline by Genzyme Corporation, H2 2015 71
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 72
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 73
Small-Cell Lung Cancer - Pipeline by Ignyta, Inc., H2 2015 74
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H2 2015 75
Small-Cell Lung Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 76
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2015 77
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 78
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015 79
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 80
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H2 2015 81
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 82
Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H2 2015 83
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H2 2015 84
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H2 2015 85
Small-Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2015 86
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 87
Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015 88
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H2 2015 89
Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2015 90
Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2015 91
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2015 92
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2015 93
Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2015 94
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015 95
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015 96
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 97
Small-Cell Lung Cancer - Pipeline by Onxeo SA, H2 2015 98
Small-Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 99
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2015 100
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H2 2015 101
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 102
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 103
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 104
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 105
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 106
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H2 2015 107
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 108
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015 109
Assessment by Monotherapy Products, H2 2015 110
Assessment by Combination Products, H2 2015 111
Number of Products by Stage and Target, H2 2015 113
Number of Products by Stage and Mechanism of Action, H2 2015 121
Number of Products by Stage and Route of Administration, H2 2015 127
Number of Products by Stage and Molecule Type, H2 2015 129
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2015 352
Small-Cell Lung Cancer - Dormant Projects, H2 2015 549
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H2 2015 550
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H2 2015 551
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H2 2015 552
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H2 2015 553
Small-Cell Lung Cancer - Dormant Projects (Contd..5), H2 2015 554
Small-Cell Lung Cancer - Discontinued Products, H2 2015 555